Skip to main content
. Author manuscript; available in PMC: 2016 Mar 3.
Published in final edited form as: Vaccine. 2015 Jan 31;33(10):1243–1249. doi: 10.1016/j.vaccine.2014.10.040

Fig 1.

Fig 1

Results of commonly used serology-based tests are inconclusive with regard to HIV infection status in participants with VISR. The tests may not differentiate between vaccine-induced antibodies and antibodies present as a result of an HIV infection. Trial participants with VISR may be incorrectly perceived as being HIV-positive. Because the person with vaccine-induced antibodies could still become infected with HIV, VISR-status may lead to delayed diagnosis of infection.